IsoRay, Inc. Common Stock (DE)

Good afternoon, ladies and gentlemen, and welcome to the ISRAE Inc. Fourth Quarter Fiscal Year 2022 call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Mark Levin. Sir, the floor is yours.

Thank you, Operator. Good afternoon, and thank you for joining us today for the discussion of the proposed merger with viewpoint molecular targeting in the ICER-A fiscal fourth quarter 2022 and fiscal year 2022 full year earnings results for the quarter and fiscal year ended June 30th, 2022. Before we get started, I will take a few minutes to read the forward-looking statement. Certain statements in this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. When used in this conference call, words such as will, believe, expect, anticipate, encourage, and similar expressions as they relate to the company or its management, as well as assumptions made by and information currently available to the company's management, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and beliefs about future events as of today, September 28, 2022, including statements regarding the anticipated synergies and benefits of the proposed merger with viewpoint molecular targeting. As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances, and the company undertakes no obligation to and expressly disclaims any obligation to update or alter its forward-looking statements, whether resulting from such changes, new information, subsequent events, or otherwise. Risk and uncertainties include whether the proposed merger is completed, and if so, whether the anticipated benefits of the merger are realized, whether an event occurs, including an event with a material adverse effect or a condition to closing the merger is not satisfied, such as failure to obtain approval from ISRA stockholders that results in a failure to complete the merger, whether ISRA and Viewpoint are able to successfully integrate their businesses, and whether restrictions on ISRA's business during the pendency of the merger harm our business. Additional information concerning forward-looking statements is contained under the headings of Safe Harbor Statement and Risk Factors listed from time to time in the company's filings with the Securities and Exchange Commission. We will begin today's call with Lori Woods, ISRA's Chief Executive Officer, and Tay Spohr, Chief Executive Officer of Viewpoint Molecular Targeting, and then Jonathan Hunt, ISRA's Chief Financial Officer, will discuss the fiscal fourth quarter and fiscal year 2022 financial results. Following their prepared remarks, we will take questions from our analysts and institutional investors. I will now turn the call over to Lori.

Thank you, Mark. Good afternoon, and thank you for joining us today. With us on the call is Taze Spohr, CEO of Viewpoint Molecular Targeting. Together we'll be discussing the proposed merger of our two companies that was announced this afternoon. Following our discussion, Jonathan Hunt and I will discuss our fourth quarter and full year results. The proposed merger with Viewpoint Molecular Targeting represents a culmination of a long and rigorous process. Throughout our strategic evaluations of opportunities over the past year and a half, we have examined the evolving therapies and approaches that signal the future of cancer treatments. In line with our focus on treating cancers from the inside out, one therapeutic area that has been of great interest to us is targeted alpha therapy. We have been following it closely and we believe that it has significant potential. As a result, and after careful consideration, it is our belief that the merger with Viewpoint represents a solid fit with IsoRay's existing business. It enters us into an initial market opportunity we believe has the potential of being a multi-billion dollar market for the first two products targeting melanoma and neuroendocrine cancers. Viewpoint's treatment approach utilizes alpha-admitting radionuclides to kill cancer cells while minimizing toxic effects. It is this powerful targeted radioactive approach, similar to cesium-131 brachytherapy, which led us to Viewpoint. The Viewpoint team has developed a platform of unique targeted alpha therapy radiopharmaceuticals using lead 212 that produces alpha particle radiation at the site of the tumor. It works together with complementary imaging agents which can be used to diagnose and then treat cancers. This form of treatment targets the specific cancer being addressed, treating the cancerous area and limiting impact on healthy parts of the body, much like cesium-131. Patients could benefit from this personalized targeted approach that is critical structure sparing, again, like cesium-131. Lead 212's limited half-life and high potency presents what we believe is an effective treatment of tumors while limiting the damage to healthy tissues. It is our view, as it is of many in the field, that this type of treatment represents the future of cancer treatment. We at ISRAE are very excited to join Viewpoint and be a catalyst to advance the efforts to bring this technology to patients around the world. From our vantage point, this merger joins two like-minded medical and biotechnology companies and the right balance of resources and personnel. These elements provide the fuel to drive both companies forward in the shared belief that personalized targeted medicine that spares patients the difficult side effects of so many existing treatments is the future of cancer therapy. To give you greater detail on Viewpoint's targeted therapies and his thoughts on the importance of the proposed merger, I am very pleased to introduce Viewpoint CEO, Taze Spohr.